20172-97-8

Basic information

• Product Name: N,N'-Di-2-pyridinylethanediamide
• Synonyms: N,N'-Bis(2-pyridyl)oxalamide;N,N'-Di-2-pyridinylethanediamide;N,N'-dipyridin-2-yloxamide
• CAS NO: 20172-97-8
• Molecular Formula: C12H10N4O2
• Molecular Weight: 242.23
• Mol File: 20172-97-8.mol
• Article Data: 7

Chemical Properties

• Melting Point: 119-120 ºC
• Appearance: /
• Density: 1.425
• Storage Temp.: 2-8°C
• PKA: 9.49±0.70(Predicted)
• CAS DataBase Reference: N,N'-Di-2-pyridinylethanediamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N'-Di-2-pyridinylethanediamide(20172-97-8)
• EPA Substance Registry System: N,N'-Di-2-pyridinylethanediamide(20172-97-8)

Safety Data

• Hazardous Substances Data: 20172-97-8(Hazardous Substances Data)

Usage

General Description

N,N'-Di-2-pyridinylethanediamide, also known as Dipyridamole, is a synthetic drug that belongs to the class of anticoagulants or platelet aggregation inhibitors. This chemical is commonly used to prevent blood clots and to reduce the risk of stroke or heart attack in individuals who have had heart valve replacements or previous heart attacks. It works by inhibiting the uptake of adenosine into platelets and has an anti-inflammatory effect on the blood vessels, helping to prevent clot formation. Additionally, N,N'-Di-2-pyridinylethanediamide may also have potential applications in cancer treatment due to its ability to inhibit tumor cell growth and angiogenesis. However, it is important to note that this chemical should only be used under the supervision of a healthcare professional, as it may have potential side effects and drug interactions.

Upstream product

• 504-29-0 2-aminopyridine 
• 79-37-8 oxalyl dichloride 
• 95-92-1 oxalic acid diethyl ester 
• 553-90-2 Dimethyl oxalate 
• 141-97-9 ethyl acetoacetate 
• 5029-67-4 2-iodopyridine 
• 471-46-5 Oxalamide 

Relevant articles and documents

Inhibitors of fumarylacetoacetate hydrolase domain containing protein 1 (Fahd1)

FAH domain containing protein 1 (FAHD1) acts as oxaloacetate decarboxylase in mitochondria, contributing to the regulation of the tricarboxylic acid cycle. Guided by a high-resolution X-ray structure of FAHD1 liganded by oxalate, the enzymatic mechanism of substrate processing is analyzed in detail. Taking the chemical features of the FAHD1 substrate oxaloacetate into account, the potential inhibitor structures are deduced. The synthesis of drug-like scaffolds afforded first-generation FAHD1-inhibitors with activities in the low micromolar IC50 range. The investigations disclosed structures competing with the substrate for binding to the metal cofactor, as well as scaffolds, which may have a novel binding mode to FAHD1.

Reagent Design and Ligand Evolution for the Development of a Mild Copper-Catalyzed Hydroxylation Reaction

Parallel synthesis and mass-directed purification of a modular ligand library, high-throughput experimentation, and rational ligand evolution have led to a novel copper catalyst for the synthesis of phenols with a traceless hydroxide surrogate. The mild reaction conditions reported here enable the late-stage synthesis of numerous complex, druglike phenols.

Crystal structure and DNA-binding study of a monoclinic polymorph of N,N′-bis(2-pyridyl)oxamide

A monoclinic polymorph of N,N′-bis(2-pyridyl)oxamide has been synthesized and characterized by single-crystal X-ray diffract ion method. It crystallizes in monoclinic, space group C2/c with crystallographic data: a = 10.596(3) A, b = 12.950(3) A, c = 8.612(2) A, β = 90.935(8)° and Z = 4. In the polymorph, two-dimensional network is formed by hydrogen bond and π-π stacking interact ion. The binding studies of the compound with calf thymus DNA (CT-DNA) have also been explored by elect ronic absorpt ion t it rat ion and fluorescence quenching experiments, and the results suggest that the compound binds to CT-DNA through groove binding.